Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

Theriva Biologics ( ($TOVX) ) just unveiled an update. On December 29, 2025, Theriva Biologics reported that it received positive Scientific ...

Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily oral peptide—has passed a phase 3 checkpoint with results that could pad ...

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The study, Step-Up HS, will evaluate Rinvoq ...

SE stock is rated Hold due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Click here for more on ARGX.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Use of alternative endpoints in phase 3 oncology trials ...

Research into clinical uses for psychedelics has proliferated in recent years, but despite the constant stream of "psychedelic renaissance" news, the vast majority of studies remain in early, ...

Having played a bit of football in my day, I often relate business concepts to sports. Regardless of whether or not you’re a sports fan, a sports metaphor can help take a complicated and cumbersome ...